PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Tofacitinib - Inflammatory bowel disease

PAD Profile : Tofacitinib - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, IBD, high cost immunomodulator, Sequential use of biologic medicines , JAK inhibitor, Janus Kinase, UC, Jakinib
Brand Names Include :
Xeljanz
Important Information :
Ulcerative colitis - adults only

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 October 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found here - https://surreyccg.res-systems.net/PADFormularyV1Admin/Profile/Detail/7986 

06 February 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee (APC) recommends tofacitinib as a treatment option in adult patients with moderately to severely active ulcerative colitis in line with NICE TA 547 (November 2018)

Tofacitinib is a payment by results excluded medicine and initiation and subsequent monitoring of response will be by the gastroenterology specialist service. Blueteq forms for initiation and continuation will be available for completion by specialist teams.

Tofacitinib will be considered as RED on the traffic light system

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More